Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ALXN1820 in Healthy Participants
NCT04631562Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in complement deficiency and sickle cell disease (SCD) comparing ALXN1820 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-related Adverse Events at Day 155. Started Jan 2021; status: completed.
02
Drugs
tarperprumig
03
Conditions
complement deficiencysickle cell disease (SCD)
Beyond the preview
Go deeper on NCT04631562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631562.